News
INCY
122.22
+1.71%
2.06
Incyte price target raised to $130 from $110 at Piper Sandler
TipRanks · 6h ago
Weekly Report: what happened at INCY last week (0810-0814)?
Weekly Report · 7h ago
IHF: Healthcare Dashboard For August
Seeking Alpha · 1d ago
Top Incyte Executive Makes Major Move With Fresh Stock Sale
TipRanks · 2d ago
Incyte Earnings Call: Growth Surges, Costs Climb
TipRanks · 2d ago
Stock index futures largely flat after S&P 500 closes at record high
Seeking Alpha · 3d ago
Analysts Offer Insights on Healthcare Companies: HealthStream (HSTM), Incyte (INCY) and Hyperion DeFi (HYPD)
TipRanks · 4d ago
Incyte (INCY), What Is Behind The Latest Attention?
Simply Wall St · 5d ago
Regeneron, Tenet leads top healthcare companies with highest earnings beats
Seeking Alpha · 5d ago
What Incyte (INCY)'s Expanded Opzelura EU Approval Means For Shareholders
Simply Wall St · 08/10 13:33
Weekly Report: what happened at INCY last week (0803-0807)?
Weekly Report · 08/10 10:10
Top Incyte Insiders Cash In On Major Stock Sale Moves
TipRanks · 08/08 02:03
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 08/07 15:30
Incyte’s EXCALIBUR-ET2 Trial Targets a New Edge in Essential Thrombocythemia
TipRanks · 08/06 16:40
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biodesix (BDSX), Incyte (INCY) and Zimmer Biomet Holdings (ZBH)
TipRanks · 08/06 13:50
REGN or INCY: Which Is the Better Value Stock Right Now?
NASDAQ · 08/05 15:40
Incyte (INCY) Could Be 5% Overvalued Following Opzelura Approval And Higher Guidance
Simply Wall St · 08/05 08:19
Top Incyte Insiders Quietly Cash In On Major Stock Sale
TipRanks · 08/05 02:06
Mizuho Maintains Outperform on Incyte, Raises Price Target to $137
Benzinga · 08/04 18:12
Incyte price target raised to $137 from $121 at Mizuho
TipRanks · 08/04 12:17
More
Webull provides a variety of real-time INCY stock news. You can receive the latest news about Incyte Corp through multiple platforms. This information may help you make smarter investment decisions.
About INCY
Incyte Corporation is a biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics. It operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise consists of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. It also includes VGA039, a novel monoclonal antibody in Phase III development for von Willebrand disease (VWD). It manages business activities through the development and commercialization of oncology and dermatology products.